trial

Brain Imaging, Cognitive Enhancement and Early Schizophrenia

NCTId NCT01561859
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 102 (actual)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2018-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
102 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2012-06
Primary completion
2018-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Cognitive Enhancement TherapyEnriched Supportive Therapy

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor
University of Pittsburgh Medical CenterCollaborator
Massachusetts General HospitalCollaborator
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Matcheri S. Keshavan, MDPrincipal Investigator

Sites

5 total
Boston, United StatesCambridge, United StatesCharlestown, United StatesPittsburgh, United StatesPittsburgh, United States

Facts & assertions

4 sourced
Enrollment
102
Phase
NA
Primary Completion Date
2018-06
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Enhancement Therapy
drug
Enriched Supportive Therapy
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
collaborator
University of Pittsburgh Medical Center
company
Massachusetts General Hospital
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Matcheri S. Keshavan, MD
person